BMYCelgeneRunning, no new patients
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
Multiple Myeloma
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 1/2
- Patients
- 466 (final count)
- Started
- Oct 14, 2016
- Main results expected
- May 9, 2024
- Fully finished
- Jul 28, 2028
- Results posted
- Mar 20, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants With Dose Limiting Toxicities in Part 1.
Measured over: From first dose to 28 days post last dose (up to 28 days)
Overall Response Rate (ORR) in Cohort D and Cohort H2
Measured over: Approximately on average (Cohort D: 21.14 weeks, Cohort H2: 22.11 Weeks)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT02773030 · record last updated 2026-03-20 · checked 2026-11-09 15:47 UTC